Anesthesia, Neuromuscular Blockade, Postoperative Complications
Conditions
Keywords
sugammadex, rocuronium, vecuronium
Brief summary
The purpose of this observational study is to evaluate patients who are planning to administer sugammadex after rocuronium or vecuronium is used. The main questions it aims to answer are: 1. Prescription pattern of sugammadex 2. Effectiveness and safety of sugammadex Since this study is observational, only data generated under daily treatment are to be collected, and no additional tests or drug administration is conducted for the study. The patients are observed from baseline to 24 hours after the initial administration of sugammadex.
Interventions
DRUGSugammadex
As this is a non-interventional study designed to collect data as part of routine clinical practice, the type and dose of neuromuscular blocking agents are all based on the clinician's judgment.
Sponsors
Boryung Pharmaceutical Co., Ltd
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female adults aged 19 or older * Is to undergo elective surgery under general anesthesia * Is planned to use rocuronium or vecuronium as an NMBA * Is planned for extubation before/after being moved to the recovery room * ASA physical status I - III * Patients who have signed the informed consent after receiving information about the purpose and method of this study
Exclusion criteria
* Has myasthenia gravis or Eaton-Lambert myasthenic syndrome * Has hypersensitivity to ingredients of sugammadex, rocuronium, or vecuronium * Has received an investigational product within 12 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study. * Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Re-administration rate of sugammadex | baseline~24 hours after administration | The number and ratio of patients re-administered with sugammadex within 24 hours of the initial administration of sugammadex are evaluated. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prescription pattern of sugammadex | baseline~24 hours after administration | The ratio of patients is presented for each administered time and dose. |
| Incidence rate of postoperative residual curarization (PORC)(TOFr<0.9) | at 3 and 30 minutes after administration of sugammadex | The TOFr (train-of-four ratio) is measured at 3 and 30 minutes after administration of sugammadex. The number and ratio of patients with a TOFr \<0.9 are defined as PORC(TOFr\<0.9). The TOFr is expressed as a decimal from 0.0 up to 1.0. |
| Incidence rate of postoperative residual curarization (PORC)(TOFr<1.0) | at 3 and 30 minutes after administration of sugammadex | The TOFr (train-of-four ratio) is measured at 3 and 30 minutes after administration of sugammadex. The number and ratio of patients with a TOFr \<1.0 are defined as PORC(TOFr\<1.0). The TOFr is expressed as a decimal from 0.0 up to 1.0. |
| Analysis of clinical factors affecting sugammadex re-administration | baseline~24 hours after administration | The number and ratio of patients who had these clinical factors are evaluated. |
| Incidence rate of respiratory complications related to postoperative residual muscle relaxation after surgery | time from the first administration of sugammadex ~ 24 hours after administration | The number and ratio of patients who had respiratory complications related to postoperative residual muscle relaxation after surgery are evaluated. |
| TOFr before sugammadex administration | baseline~24 hours after administration | The TOFr (train-of-four ratio) is measured before each administration of sugammadex. The TOFr is expressed as a decimal from 0.0 up to 1.0. |
| TOFr before extubation | baseline~24 hours after administration | The TOFr (train-of-four ratio) is measured before extubation. The TOFr is expressed as a decimal from 0.0 up to 1.0. |
| Time to extubation | baseline~24 hours after administration | The time from the first administration of sugammadex or the last administration of NMBA to the time of extubation is measured in minutes. |
| Time surpassed from the expected dismissal time from the recovery room | baseline~24 hours after administration | The time of dismissal from the recovery room is recorded for each patient. |
| Ratio of unplanned transfer to the intensive care unit(excluding lung surgery and heart surgery) | time from the first administration of sugammadex ~ 24 hours after administration | The number and ratio of patients who was moved from the recovery room to the intensive care unit unplanned. |
| Incidence rate of PONV(postoperative nausea and vomiting) | time from the first administration of sugammadex ~ 24 hours after administration | The number and ratio of patients who experiences PONV(postoperative nausea and vomiting). |
| Incidence rate of adverse drug reaction | time from the first administration of sugammadex ~ 24 hours after administration | The number and ratio of patients who experiences adverse drug reactions in which their relationship to sugammadex cannot be ruled out. |
| Incidence rate of serious adverse drug reaction | time from the first administration of sugammadex ~ 24 hours after administration | The number and ratio of patients who experiences serious adverse drug reactions in which their relationship to sugammadex cannot be ruled out. |
Countries
South Korea
Contacts
PRINCIPAL_INVESTIGATORChoon-Hak Lim, MD
Department of Anesthesiology and Pain Medicine, Korea University Medical Center, Seoul, Korea.
Outcome results
None listed